Glucosylceramide synthase inhibitors prevent replication of SARS-CoV-2 and influenza virus

[1]  V. Botosso,et al.  SARS-CoV-2 isolation from the first reported patients in Brazil and establishment of a coordinated task network , 2020, Memorias do Instituto Oswaldo Cruz.

[2]  Natacha S. Ogando,et al.  SARS-coronavirus-2 replication in Vero E6 cells: replication kinetics, rapid adaptation and cytopathology , 2020, bioRxiv.

[3]  Joy Y. Feng,et al.  Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency , 2020, The Journal of Biological Chemistry.

[4]  M. Kester,et al.  Glucosylceramide synthase maintains influenza virus entry and infection , 2020, PloS one.

[5]  Carolina L. Bellera,et al.  Challenges and opportunities with drug repurposing: finding strategies to find alternative uses of therapeutics , 2019, Expert opinion on drug discovery.

[6]  M. Kester,et al.  Glucosylceramidase Maintains Influenza Virus Infection by Regulating Endocytosis , 2019, Journal of Virology.

[7]  R. Kuhn,et al.  Dynamic remodeling of lipids coincides with dengue virus replication in the midgut of Aedes aegypti mosquitoes , 2018, PLoS pathogens.

[8]  F. Bushman,et al.  A role for glycolipid biosynthesis in severe fever with thrombocytopenia syndrome virus entry , 2017, PLoS pathogens.

[9]  L. Riboni,et al.  Modulation of Neuroinflammation in the Central Nervous System: Role of Chemokines and Sphingolipids , 2017, Advances in Therapy.

[10]  S. Alves,et al.  Less Is More: Substrate Reduction Therapy for Lysosomal Storage Disorders , 2016, International journal of molecular sciences.

[11]  H. Low,et al.  Cytomegalovirus Restructures Lipid Rafts via a US28/CDC42-Mediated Pathway, Enhancing Cholesterol Efflux from Host Cells. , 2016, Cell reports.

[12]  D. Leshkowitz,et al.  Induction of the type I interferon response in neurological forms of Gaucher disease , 2016, Journal of Neuroinflammation.

[13]  Ying Sun,et al.  CNS-accessible Inhibitor of Glucosylceramide Synthase for Substrate Reduction Therapy of Neuronopathic Gaucher Disease , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[14]  R. Dwek,et al.  Iminosugars Inhibit Dengue Virus Production via Inhibition of ER Alpha-Glucosidases—Not Glycolipid Processing Enzymes , 2016, PLoS neglected tropical diseases.

[15]  J. Souza-Neto,et al.  A Lipidomics Approach in the Characterization of Zika-Infected Mosquito Cells: Potential Targets for Breaking the Transmission Cycle , 2016, PloS one.

[16]  B. Wang,et al.  Efficacy of Enzyme and Substrate Reduction Therapy with a Novel Antagonist of Glucosylceramide Synthase for Fabry Disease , 2015, Molecular medicine.

[17]  S. Packman,et al.  Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial. , 2015, JAMA.

[18]  J. Miller,et al.  Strain-specific antiviral activity of iminosugars against human influenza A viruses , 2014, The Journal of antimicrobial chemotherapy.

[19]  K. Konan,et al.  Modulation of Hepatitis C Virus Genome Replication by Glycosphingolipids and Four-Phosphate Adaptor Protein 2 , 2014, Journal of Virology.

[20]  Frances M. Platt,et al.  Sphingolipid lysosomal storage disorders , 2014, Nature.

[21]  S. Rozen,et al.  Lipidomics identifies a requirement for peroxisomal function during influenza virus replication[S] , 2014, Journal of Lipid Research.

[22]  R. Dwek,et al.  Liposome-Mediated Delivery of Iminosugars Enhances Efficacy against Dengue Virus In Vivo , 2012, Antimicrobial Agents and Chemotherapy.

[23]  R. Scheule,et al.  Systemic Delivery of a Glucosylceramide Synthase Inhibitor Reduces CNS Substrates and Increases Lifespan in a Mouse Model of Type 2 Gaucher Disease , 2012, PloS one.

[24]  Jinhong Chang,et al.  Design, synthesis, and biological evaluation of N-alkylated deoxynojirimycin (DNJ) derivatives for the treatment of dengue virus infection. , 2012, Journal of medicinal chemistry.

[25]  D. Alonzi,et al.  Inhibitors of Endoplasmic Reticulum α-Glucosidases Potently Suppress Hepatitis C Virus Virion Assembly and Release , 2010, Antimicrobial Agents and Chemotherapy.

[26]  Shayman Ja.  ELIGLUSTAT TARTRATE: Glucosylceramide Synthase Inhibitor Treatment of Type 1 Gaucher Disease. , 2010 .

[27]  N. Zitzmann,et al.  Targeting a host process as an antiviral approach against dengue virus. , 2010, Trends in Microbiology.

[28]  D. Burton,et al.  N-Butyldeoxynojirimycin is a broadly effective anti-HIV therapy significantly enhanced by targeted liposome delivery , 2008, AIDS.

[29]  H. Achdout,et al.  Influenza Virus Infection Augments NK Cell Inhibition through Reorganization of Major Histocompatibility Complex Class I Proteins , 2008, Journal of Virology.

[30]  J. Shayman,et al.  A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease. , 2007, Molecular genetics and metabolism.

[31]  Seng H. Cheng,et al.  Inhibiting Glycosphingolipid Synthesis Improves Glycemic Control and Insulin Sensitivity in Animal Models of Type 2 Diabetes , 2007, Diabetes.

[32]  Yasuo Suzuki,et al.  Suppression of the biosynthesis of cellular sphingolipids results in the inhibition of the maturation of influenza virus particles in MDCK cells. , 2006, Biological & pharmaceutical bulletin.

[33]  E. Clercq.  Antivirals and antiviral strategies , 2004, Nature Reviews Microbiology.

[34]  R. Dwek,et al.  Inhibition of hepatitis B virus DNA replication by imino sugars without the inhibition of the DNA polymerase: Therapeutic implications , 2001, Hepatology.

[35]  P. Desprès,et al.  α-Glucosidase Inhibitors Reduce Dengue Virus Production by Affecting the Initial Steps of Virion Morphogenesis in the Endoplasmic Reticulum , 2000, Journal of Virology.

[36]  R. Dwek,et al.  Hepatitis B virus (HBV) envelope glycoproteins vary drastically in their sensitivity to glycan processing: evidence that alteration of a single N-linked glycosylation site can regulate HBV secretion. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[37]  R. Dwek,et al.  N-butyldeoxynojirimycin-mediated inhibition of human immunodeficiency virus entry correlates with impaired gp120 shedding and gp41 exposure , 1996, Journal of virology.

[38]  R. Dwek,et al.  N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis. , 1994, The Journal of biological chemistry.

[39]  C. E..  WHO Coronavirus Disease (COVID-19) Dashboard , 2020 .

[40]  P. Maison-Blanche,et al.  Management and monitoring recommendations for the use of eliglustat in adults with type 1 Gaucher disease in Europe. , 2017, European journal of internal medicine.

[41]  A. Futerman,et al.  Neuronal forms of Gaucher disease. , 2013, Handbook of experimental pharmacology.

[42]  E. De Clercq,et al.  Antivirals and antiviral strategies. , 2004, Nature reviews. Microbiology.